These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31918623)

  • 1. Breast Cancer Risk in Postmenopausal Women with Medical History of Thyroid Disorder in the Women's Health Initiative.
    Weng CH; Okawa ER; Roberts MB; Park SK; Umbricht CB; Manson JE; Eaton CB
    Thyroid; 2020 Apr; 30(4):519-530. PubMed ID: 31918623
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
    Wang SM; Pfeiffer RM; Gierach GL; Falk RT
    Breast Cancer Res; 2020 Nov; 22(1):129. PubMed ID: 33239054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.
    Chlebowski RT; Anderson GL; Aragaki AK; Manson JE; Stefanick ML; Pan K; Barrington W; Kuller LH; Simon MS; Lane D; Johnson KC; Rohan TE; Gass MLS; Cauley JA; Paskett ED; Sattari M; Prentice RL
    JAMA; 2020 Jul; 324(4):369-380. PubMed ID: 32721007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperthyroidism, Hypothyroidism, and Cause-Specific Mortality in a Large Cohort of Women.
    Journy NMY; Bernier MO; Doody MM; Alexander BH; Linet MS; Kitahara CM
    Thyroid; 2017 Aug; 27(8):1001-1010. PubMed ID: 28578598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study.
    Li CI; Chlebowski RT; Freiberg M; Johnson KC; Kuller L; Lane D; Lessin L; O'Sullivan MJ; Wactawski-Wende J; Yasmeen S; Prentice R
    J Natl Cancer Inst; 2010 Sep; 102(18):1422-31. PubMed ID: 20733117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid dysfunction and breast cancer risk among women in the UK Biobank cohort.
    Tran TV; Maringe C; Benitez Majano S; Rachet B; Boutron-Ruault MC; Journy N
    Cancer Med; 2021 Jul; 10(13):4604-4614. PubMed ID: 34041857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
    Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
    J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between menopausal hormone therapy and the risk of gastric cancer: A Korean nationwide population-based cohort study.
    Han KH; Choi YJ; Han K; Shin CM; Park NH; Lee DH
    Maturitas; 2024 Jun; 184():107960. PubMed ID: 38460415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is breast cancer risk the same for all progestogens?
    Stute P
    Arch Gynecol Obstet; 2014 Aug; 290(2):207-9. PubMed ID: 24838289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chocolate Candy and Incident Invasive Cancer Risk in the Women's Health Initiative: An Observational Prospective Analysis.
    Greenberg JA; Neuhouser ML; Tinker LF; Lane DS; Paskett ED; Van Horn LV; Wassertheil-Smoller S; Shikany JM; Qi L; Sealy-Jefferson S; Manson JE
    J Acad Nutr Diet; 2021 Feb; 121(2):314-326.e4. PubMed ID: 32763064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort.
    Cadeau C; Fournier A; Mesrine S; Clavel-Chapelon F; Fagherazzi G; Boutron-Ruault MC
    Int J Cancer; 2016 Nov; 139(10):2193-200. PubMed ID: 27451078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between current vitamin D supplementation and menopausal hormone therapy use on breast cancer risk: evidence from the E3N cohort.
    Cadeau C; Fournier A; Mesrine S; Clavel-Chapelon F; Fagherazzi G; Boutron-Ruault MC
    Am J Clin Nutr; 2015 Oct; 102(4):966-73. PubMed ID: 26354532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
    Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
    Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study.
    Tjønneland A; Christensen J; Thomsen BL; Olsen A; Overvad K; Ewertz M; Mellemkjaer L
    Cancer; 2004 Jun; 100(11):2328-37. PubMed ID: 15160335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between menopausal hormone therapy, mammographic density and breast cancer risk: results from the E3N cohort study.
    Fornili M; Perduca V; Fournier A; Jérolon A; Boutron-Ruault MC; Maskarinec G; Severi G; Baglietto L
    Breast Cancer Res; 2021 Apr; 23(1):47. PubMed ID: 33865453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study.
    Chen Z; Maricic M; Bassford TL; Pettinger M; Ritenbaugh C; Lopez AM; Barad DH; Gass M; Leboff MS
    Arch Intern Med; 2005 Mar; 165(5):552-8. PubMed ID: 15767532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthropometric measures and serum estrogen metabolism in postmenopausal women: the Women's Health Initiative Observational Study.
    Oh H; Coburn SB; Matthews CE; Falk RT; LeBlanc ES; Wactawski-Wende J; Sampson J; Pfeiffer RM; Brinton LA; Wentzensen N; Anderson GL; Manson JE; Chen C; Zaslavsky O; Xu X; Trabert B
    Breast Cancer Res; 2017 Mar; 19(1):28. PubMed ID: 28284224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.
    Chlebowski RT; Rohan TE; Manson JE; Aragaki AK; Kaunitz A; Stefanick ML; Simon MS; Johnson KC; Wactawski-Wende J; O'Sullivan MJ; Adams-Campbell LL; Nassir R; Lessin LS; Prentice RL
    JAMA Oncol; 2015 Jun; 1(3):296-305. PubMed ID: 26181174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study.
    Cervenka I; Al Rahmoun M; Mahamat-Saleh Y; Savoye I; Boutron-Ruault MC; Fournier A; Kvaskoff M
    Int J Cancer; 2019 Oct; 145(7):1754-1767. PubMed ID: 30671928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition.
    Bakken K; Fournier A; Lund E; Waaseth M; Dumeaux V; Clavel-Chapelon F; Fabre A; Hémon B; Rinaldi S; Chajes V; Slimani N; Allen NE; Reeves GK; Bingham S; Khaw KT; Olsen A; Tjønneland A; Rodriguez L; Sánchez MJ; Etxezarreta PA; Ardanaz E; Tormo MJ; Peeters PH; van Gils CH; Steffen A; Schulz M; Chang-Claude J; Kaaks R; Tumino R; Gallo V; Norat T; Riboli E; Panico S; Masala G; González CA; Berrino F
    Int J Cancer; 2011 Jan; 128(1):144-56. PubMed ID: 20232395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.